Abstract Tissue destruction & many diseases motivated by chronic reactive oxygen species (ROS) accumulation. Thyroid hormones could be able to activate ROS, which represent an important mechanism in pathogenesis of cardiovascular disorder. Existing therapies preventing or slowing the progress of secondary hyperthyroid cardiovascular complications often lose effectiveness over time. A potent SIRT1 activator (resveratrol) showed to lower oxidative stress, inflammation, autophagy induction, but, its cardioprotective effects in hyperthyroid states were not systematically evaluated, so we aimed to investigate its therapeutic and molecular effects & its benefits on the indexes of hyperthyroid cardiovascular disorder. Materials and Methods: Twenty-four adult male albino rats (180-200 gm) were equally divided to; control, resveratrol administrated group (rats received oral resveratrol 10 mg/kg/day/4 weeks), experimentally-induced hyperthyroid group (rats received oral L-thyroxin 300 mg/kg of body weight for 4weeks) and resveratrol-administrated hyperthyroid group (L-thyroxin + resveratrol through oral gavage for 4weeks). Finally, body weight, heart rate (HR), blood pressure (BP), vascular reactivity to NE and % of increase in mean ABP measurements, cardiac hypertrophy index (CHI) were estimated. Blood samples were withdrawn for examinations. After scarification, fresh cardiac & aortic specimens were collected for biochemical, gene expression and histological examination. Results: A statistically significant improvements were found in resveratrol-administrated hyperthyroid group versus hyperthyroid group as regard HR, BP, vascular reactivity to NE and % of increase in mean ABP measurements, along with restoration of CHI, serum thyroid hormones, SIRT-1 cardiac activity and downregulation of IL-6 & TNF-α gene expression. Furthermore, there were significantly reduction of cardiac oxidant, inflammatory & fibrotic pathways. Conclusion: our study suggested that SIRT1 activator (resveratrol) usage would carry a large promise to reduce cardiac & vascular risks in hyperthyroid states by improving of HR, BP measurements and vascular reactivity, moreover, reversal of cardiac (SIRT 1activity/inflammatory/oxidative stress/fibrotic biomarkers).